Dare Bioscience Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.535
- Today's High:
- $0.555
- Open Price:
- $0.535
- 52W Low:
- $0.82
- 52W High:
- $1.465
- Prev. Close:
- $0.544
- Volume:
- 109123
Company Statistics
- Market Cap.:
- $86.23 million
- Book Value:
- 0.058
- Revenue TTM:
- $10 million
- Operating Margin TTM:
- -313.68%
- Gross Profit TTM:
- $9.90 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -49.29%
- Return on Equity TTM:
- -170.66%
Company Profile
Dare Bioscience Inc had its IPO on 2014-04-10 under the ticker symbol DARE.
The company operates in the Healthcare sector and Biotechnology industry. Dare Bioscience Inc has a staff strength of 25 employees.
Stock update
Shares of Dare Bioscience Inc opened at $0.54 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.54 - $0.56, and closed at $0.54.
This is a -1.64% slip from the previous day's closing price.
A total volume of 109,123 shares were traded at the close of the day’s session.
In the last one week, shares of Dare Bioscience Inc have slipped by -21.31%.
Dare Bioscience Inc's Key Ratios
Dare Bioscience Inc has a market cap of $86.23 million, indicating a price to book ratio of 2.8971 and a price to sales ratio of 7.6682.
In the last 12-months Dare Bioscience Inc’s revenue was $10 million with a gross profit of $9.90 million and an EBITDA of $-31339204. The EBITDA ratio measures Dare Bioscience Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Dare Bioscience Inc’s operating margin was -313.68% while its return on assets stood at -49.29% with a return of equity of -170.66%.
In Q1, Dare Bioscience Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Dare Bioscience Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.36 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Dare Bioscience Inc’s profitability.
Dare Bioscience Inc stock is trading at a EV to sales ratio of 3.6536 and a EV to EBITDA ratio of -1.4805. Its price to sales ratio in the trailing 12-months stood at 7.6682.
Dare Bioscience Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $30.37 million
- Total Liabilities
- $24.34 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Dare Bioscience Inc ended 2024 with $30.37 million in total assets and $0 in total liabilities. Its intangible assets were valued at $30.37 million while shareholder equity stood at $4.97 million.
Dare Bioscience Inc ended 2024 with $0 in deferred long-term liabilities, $24.34 million in other current liabilities, 8618.00 in common stock, $-149117141.00 in retained earnings and $0 in goodwill. Its cash balance stood at $19.83 million and cash and short-term investments were $19.83 million. The company’s total short-term debt was $335,764 while long-term debt stood at $0.
Dare Bioscience Inc’s total current assets stands at $29.51 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $2.40 million compared to accounts payable of $2.70 million and inventory worth $0.
In 2024, Dare Bioscience Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Dare Bioscience Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.54
- 52-Week High
- $1.465
- 52-Week Low
- $0.82
- Analyst Target Price
- $5.5
Dare Bioscience Inc stock is currently trading at $0.54 per share. It touched a 52-week high of $1.465 and a 52-week low of $1.465. Analysts tracking the stock have a 12-month average target price of $5.5.
Its 50-day moving average was $0.74 and 200-day moving average was $0.95 The short ratio stood at 2.46 indicating a short percent outstanding of 0%.
Around 192.9% of the company’s stock are held by insiders while 852.3% are held by institutions.
Frequently Asked Questions About Dare Bioscience Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women’s health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company’s product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder; and DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy. The company’s Phase I-ready products are DARE-VVA1, a proprietary formulation of tamoxifen for intravaginal to treat vulvar vaginal atrophy in women with hormone-receptor positive breast cancer; DARE-PDM1, a proprietary hydrogel formulation of diclofenac, a nonsteroidal anti-inflammatory drug, for vaginal administration as a treatment for dysmenorrhea; DARE-204 and DARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-GML, an intravaginally-delivered potential multi-target antimicrobial agent formulated with glycerol monolaurate; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal healt